Actinogen Medical Limited

As of June 30, 2026, Actinogen Medical Limited carries a market capitalization of 115.23M, placing it among publicly traded companies globally. Its enterprise value stands at 103.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Actinogen Medical Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Actinogen Medical Limited has 3.72B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Actinogen Medical Limited maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.38, indicating elevated leverage, while an interest coverage ratio of -59.44 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Actinogen Medical Limited posted a negative return on equity (ROE) of -77.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.92, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Actinogen Medical Limited's stock has gained approximately 31.43% over the past 52 weeks. The 50-day moving average sits at 0.05, while the 200-day moving average is 0.04.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -27.69M, while operating income came in at -28.11M.

As of June 30, 2026, Actinogen Medical Limited holds 16.73M in cash and equivalents against 4.78M in total debt, resulting in a net debt position of -12.12M. Total book value stands at 21.37M, with working capital of 19.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -15.45, meaning Actinogen Medical Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Actinogen Medical Limited's most recent stock split took place on May 9, 2024 with a 72:73 split ratio.